Review the dosing and administration instructions for the appropriate indication below by clicking on the corresponding tabs.
Be sure to provide and instruct patients to read the XOLAIR Medication Guide before starting treatment and before each subsequent treatment.
The patient's pretreatment serum total immunoglobulin E (IgE) level (IU/mL), and body weight (lb or kg) are used to determined doses (mg) and dosing frequency.1 For adult patients with both asthma and nasal polyps, dosing determination should be based on the primary diagnosis for which XOLAIR is being prescribed.
Use the dosing tool below to determine the recommended dosing for your patients.
To determine how much XOLAIR to administer in a dose, enter the patient’s weight (in lb or kg), pretreatment serum IgE (IU/mL) level, and age.
Dosing Tool is intended for US healthcare professionals only.
For patients aged 6 to <12 years whose pretreatment serum total IgE level or body weight is outside the limits of the dosing table (<30 or >1300 IU/mL and <44 or >330 lb, respectively), there is insufficient data to recommend a dose.1
For patients aged ≥12 years whose pretreatment serum total IgE level or body weight is outside the limits of the dosing table (<30 or >700 IU/mL and <66 or >330 lb, respectively), there is insufficient data to recommend a dose.1
Doses of more than 150 mg are divided among more than 1 injection site to limit injections to not more than 150 mg per site.1
Injection Site Reactions
Asthma
In adults and adolescents with asthma, injection site reactions of any severity occurred at a rate of 45% in XOLAIR-treated patients compared with 43% in placebo-treated patients. Severe injection site reactions occurred more frequently in XOLAIR‑treated patients compared with patients in the placebo group (12% vs 9%, respectively). The types of injection site reactions in asthma studies included: bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation.
Dosing is based on pretreatment serum total IgE level from 30 up to 1300 IU/mL and body weight of 44 to 330 lb.
Doses of more than 150 mg are divided among more than 1 injection site to limit injections to not more than 150 mg per site.1
The table below shows the number of prefilled syringes or vials per dose, the number of injections per dose, and the total volume to be injected.
*The 75 mg, 150 mg, 225 mg, 300 mg, and 375 mg XOLAIR doses are approved for use in asthma patients.
*The 75 mg, 150 mg, 225 mg, 300 mg, and 375 mg XOLAIR doses are approved for use in asthma patients.
†1.2 mL maximum delivered volume per vial after reconstitution.
Total IgE levels are elevated during treatment and remain elevated for up to 1 year after the discontinuation of treatment. Retesting of IgE levels during XOLAIR treatment cannot be used as a guide for dose determination.
Dose determination after treatment interruptions lasting less than 1 year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be retested for dose determination if treatment with XOLAIR has been interrupted for 1 year or more.
Doses should be adjusted for significant changes in body weight according to the dosing tables.
Dosing of XOLAIR in CSU patients is NOT dependent on serum IgE (free or total) level or body weight.1
The appropriate duration of therapy for XOLAIR has not been evaluated. Periodically reassess the need for continued therapy. 1
Flat-Fixed Dosing for CSU
Know Your Options When Prescribing XOLAIR
Be sure to provide and instruct patients to read the XOLAIR Medication Guide before starting treatment and before each subsequent treatment.
IgE=immunoglobulin E.
Injection Site Reactions
Chronic Spontaneous Urticaria
Injection site reactions of any severity occurred in more XOLAIR-treated patients (11 patients [2.7%] at 300 mg, 1 patient [0.6%] at 150 mg) compared with 2 placebo-treated patients (0.8%). The types of injection site reactions included: swelling, erythema, pain, bruising, itching, bleeding, and urticaria. None of the events resulted in study discontinuation or treatment interruption.
The patient's pretreatment serum total immunoglobulin E (IgE) level (IU/mL), and body weight (lb or kg) are used to determine doses (mg) and dosing frequency.1 For adult patients with both asthma and nasal polyps, dosing determination should be based on the primary diagnosis for which XOLAIR is being prescribed.
Use the dosing tool below to determine the recommended dosing for your patients.
To determine how much XOLAIR to administer in a dose, and how frequently to administer XOLAIR in adult patients 18 years of age or older, enter the patient's weight (in lb or kg) and pretreatment serum IgE (IU/mL) level.
Dosing Tool recommendations are based on Table 3 in the Prescribing Information.
Dosing Tool is intended for US healthcare professionals only.
For patients 18 years of age or older whose pretreatment serum total IgE level or body weight is outside the limits of the dosing table (<30 or >1500 IU/mL and <66 or >331 lb, respectively), there is insufficient data to recommend a dose.
Total IgE levels are elevated during treatment and remain elevated for up to 1 year after the discontinuation of treatment. Retesting of IgE levels during XOLAIR treatment cannot be used as a guide for dose determination.
Dose determination after treatment interruptions lasting less than 1 year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be retested for dose determination if treatment with XOLAIR has been interrupted for 1 year or more.
Doses should be adjusted for significant changes in body weight according to the dosing table.
Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
The table below shows the number of prefilled syringes or vials per dose, the number of injections per dose, and the total volume to be injected.
*The 75 mg, 150 mg, 225 mg, 300 mg, and 375 mg XOLAIR doses are approved for use in asthma patients. All doses in the table are approved for use in nasal polyps patients. The 150 mg and 300 mg XOLAIR doses are also approved for use in CSU patients.
*The 75 mg, 150 mg, 225 mg, 300 mg, and 375 mg XOLAIR doses are approved for use in asthma patients. All doses in the table are approved for use in nasal polyps patients. The 150 mg and 300 mg XOLAIR doses are also approved for use in CSU patients.
†1.2 mL maximum delivered volume per vial after reconstitution.
Total IgE levels are elevated during treatment and remain elevated for up to 1 year after the discontinuation of treatment. Retesting of IgE levels during XOLAIR treatment is unnecessary and cannot be used as a guide for dose determination.
Dose determination after treatment interruptions lasting less than 1 year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be retested for dose determination if treatment with XOLAIR has been interrupted for 1 year or more.
Doses should be adjusted for significant changes in body weight according to the dosing tables.
Injection Site Reactions
Nasal Polyps
Injection site reactions occurred at a rate of 5.2% in XOLAIR-treated patients compared with 1.5% in placebo-treated patients. Injection site reactions were mild to moderate severity and none resulted in study discontinuation.
If the XOLAIR prescribed for a labeled indication was spoiled or unable to be administered, the Genentech Spoilage Replacement Program might be able to provide you with a new supply.‡
‡Subject to certain limitations and conditions. The Spoilage Replacement Program covers infused or injected Genentech products.
For additional resources for you and your staff related to procurement, distribution, spoilage, and reimbursement, visit Access Solutions. To learn if financial support is available for your patient, click here.
XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.
XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.
Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.
Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.
Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/
Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/
World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.
World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.
Data on file. Genentech USA, Inc. South San Francisco, CA.
Data on file. Genentech USA, Inc. South San Francisco, CA.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.
Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.
Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.
Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.
Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.
Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.
Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.
Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.
Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.
Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.
Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.
Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.
Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.
Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.
Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.
Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.
Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.
National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.
National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.
Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.
Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.
Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/2315/immunocap-ref-range_test-menu_0318.pdf. Accessed March 19, 2020.
Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/2315/immunocap-ref-range_test-menu_0318.pdf. Accessed March 19, 2020.
Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.
Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.
Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.
Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.
Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.
Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.
Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.
Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.
Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.
Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.
Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.
Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.
Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.
Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.
Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.
Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.
Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.
Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.
Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.
Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.
Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.
Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.
Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.
Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.
US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.
US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.
XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.
XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.
Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.
Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.
Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/
Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/
World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.
World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.
Data on file. Genentech USA, Inc. South San Francisco, CA.
Data on file. Genentech USA, Inc. South San Francisco, CA.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.
Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.
Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.
Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.
Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.
Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.
Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.
Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.
Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.
Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.
Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.
Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.
Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.
Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.
Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.
Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.
Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.
National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.
National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.
Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.
Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.
Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/
2315/immunocap-ref-range_test-menu_0318.pdf.
Accessed March 19, 2020.
Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/
2315/immunocap-ref-range_test-menu_0318.pdf.
Accessed March 19, 2020.
Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.
Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.
Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.
Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.
Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.
Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.
Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.
Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.
Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.
Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.
Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.
Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.
Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.
Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.
Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.
Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.
Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.
Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.
Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.
Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.
Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.
Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.
Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.
Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.
Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.
US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.
US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.